Natco Pharma is a pharmaceutical company built on patience: it spends years-sometimes a decade-developing complex, hard-to-copy generic drugs, then reaps the rewards when it is first to challenge a patent or launch in a market with almost no competition. Founded in Hyderabad in 1981, it rose to prominence by pioneering branded oncology therapies in India, then took that chemistry expertise into the United States, where its ability to overturn patents on blockbuster drugs like Revlimid turned it into a serious player. The recurring approach is a refusal to compete on volume: Natco hunts for niche, high-barrier molecules-drugs that are difficult to make, hard to deliver, or protected by dense patents-and builds its business around the few years of limited competition that follow a successful launch.
Business segments
Three engines, one chemical core-a global generics machine that challenges patents on complex drugs, a domestic branded business built on oncology leadership, and a young crop-science division spun from the same chemistry skills.
1. Export formulations: the patent-challenge engine
Natco makes complex generic drugs, mostly for the US market, and earns money by being first to break a patent-then splitting the profits with a marketing partner who handles sales and litigation.
- First-to-file is the moat - the company targets drugs with limited competition by filing Paragraph IV patent challenges, and as of March 2026 it had 28 such filings in the US, with over 20 First-to-File opportunities that give it a head start when a patent falls.
- Partners sell, Natco makes - in the US, marketing partners like Sun Pharma, Alvogen, and Teva handle distribution and legal battles, while Natco focuses on R&D and manufacturing, receiving a share of the profit rather than building its own sales army.
- The pipeline is the future - key solo First-to-File products in the queue include generic versions of Ozempic (semaglutide pen) for diabetes, Wegovy for weight loss, Lynparza (olaparib) for ovarian and breast cancer, and Imbruvica (ibrutinib) for leukaemia.
- A direct US shop, slowly - Natco bought its own front-end subsidiary, Dash Pharmaceuticals LLC (later renamed NATCO Pharma USA LLC), in 2022 for US$ 18 million to launch simpler generics under its own label, though it was still loss-making as of mid-FY26.
- Beyond America - the export engine reaches over 50 countries through subsidiaries in Canada, Brazil, and Australia, plus tenders in Saudi Arabia, Egypt, and Southeast Asia; in Canada, Natco ranks among the top 10 generic firms and holds the highest market share for lenalidomide.
2. Domestic formulations: the branded oncology anchor
Natco is a market leader in branded oncology in India, selling over 40 cancer drugs through a specialist sales force that reaches roughly 60,000 doctors, and is now expanding into cardiology and diabetes.
- Oncology pioneer - the company has been in Indian oncology for over two decades, growing from 6 brands in 2003-04 to more than 40, with 9 brands crossing ₹100 million in annual sales and 25 holding leading positions in their class.
- Specialist reach, not mass-market - a sales force of over 850 sales professionals calls on approximately 60,000 doctors, supported by more than 1,000 distributors, with a deliberate push into Tier-2 and Tier-3 towns.
- Four therapy divisions - the business is split into Oncology, Pharma Specialty (covering hepatitis, orthopaedics, and virology), Cardiology, and Diabetology, with an additional infectious-disease division called Dynami.
- First-to-market launches - most domestic launches are first-time generics in India, including Risdiplam for Spinal Muscular Atrophy and affordable Semaglutide vials for diabetes, both launched in FY26.
- A pipeline of over 80 brands - the domestic business targets roughly 10 product launches a year from a branded-generic pipeline of more than 80 products.
3. Crop Health Sciences: chemistry applied to fields
Natco took its skills in complex chemical synthesis and patent law into agrochemicals, focusing on niche insecticides and pheromone-based pest control, and is now preparing to list the division as a separate company.
- Born from pharma chemistry - the division emerged from Natco's expertise in difficult synthesis and patent knowledge, targeting high-value crop-protection products rather than commodity pesticides.
- The landmark product is CTPR - Natco was the first Indian company to win approval for indigenous manufacture of Chlorantraniliprole, a broad-spectrum insecticide whose market in India is estimated at over ₹2,000 crores, and launched it under the brand NATGEN after winning a patent battle with FMC Corporation.
- Pheromones, not just poisons - the division pioneered pheromone-based mating-disruption technology in India, launching NATMATE PBW for pink bollworm in cotton, the first indigenously manufactured product of its kind approved by the Central Insecticide Board.
- Domestic, direct, and distributor-fed - 90% of sales come from direct customer interaction, served by a sales team of over 300 people, 3,000 distributors, and coverage across 126 districts, backed by TV advertising and on-ground activations.
- Heading for a separate listing - in March 2026, the board approved a demerger of the division into Natco Crop Health Sciences Limited; post-scheme, shareholders will directly own about 80% of the new entity, which is proposed to be listed on Indian stock exchanges.
Group structure and partners
Natco runs its international business through a network of wholly owned subsidiaries in roughly ten countries, while its US engine relies on profit-sharing partnerships with large generic-drug marketers; a recent US$ 226 million stake in South Africa's Adcock Ingram adds a major African affiliate.
- The Adcock Ingram stake - in November 2025, Natco acquired 35.75% of Adcock Ingram, South Africa's second-largest pharmaceutical company by private-market share and the leader in hospital and critical-care products, for approximately US$ 226 million; Adcock was delisted and now operates as a private company with Bidvest holding the remaining 64.25%.
- US partners carry the legal risk - the American business is built on partnerships with Sun Pharma, Alvogen, Teva, Mylan, and others who handle litigation and distribution, while Natco supplies the product and shares the profit.
- Strategic biotech bets - Natco has placed small investments in early-stage biotech firms to access capabilities it lacks internally: US$ 8 million in eGenesis (xenotransplantation), US$ 2 million in Cellogen Therapeutics (CAR-T cell therapy), and US$ 1 million in Stero Therapeutics (novel therapy for metabolic diseases).